Search

Your search keyword '"Taszner, M."' showing total 2 results
Start Over Author "Taszner, M." Topic lymphomas
2 results on '"Taszner, M."'

1. AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL). REAL‐WORLD REPORT OF POLISH LYMPHOMA RESEARCH GROUP.

Author

Ostrowska, B., Domanska‐Czyz, K., Giza, A., Taszner, M., Romejko‐Jarosinska, J., Targonski, L., Poplawska, L., Konecki, R., Kotarska, M., Szymanski, M., Borawska, A., Swierkowska, M., Dabrowska‐Iwanicka, A., Druzd‐Sitek, A., Paszkiewicz‐Kozik, E., Mroz‐Zycinska, E., Osowiecki, M., Zimowska‐Curylo, D., Owczarek‐Kaczmarek, J., and Tajer, J.

Subjects
STEM cell transplantation, HEMATOPOIETIC stem cell transplantation, CENTRAL nervous system, RESEARCH teams, LYMPHOMAS
Abstract

B Conclusion: b HDC-ASCT based on conditioning regimen consisted of carmustine, etoposide and thiotepa (BET) is a relatively safe and highly effective treatment for PCNSL patients. B Introduction: b High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is now the preferred consolidation strategy for young PCNSL patients. At the end of induction 29 (64.5%) patients obtained CR/CRun (19/10 respectively), with additional 5 (11%) patients with no evidence of disease at baseline, and 11 (24.5%) in PR, based on standard CT/MRI assessment. [Extracted from the article]

Published
2023
Full Text
View/download PDF

2. Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study.

Author

Paszkiewicz‐Kozik, E., Kurlapski, M., Swoboda, R., Subocz, E., Szymanski, M., Taszner, M., Wicherska‐Pawlowska, K., Koclega, A., Domanska‐Czyz, K., Swierkowska, M., Woszczyk, D., Targonski, L., Chmielowska, E., Dabrowska‐Iwanicka, A., Ostrowska, B., Romejko‐Jarosinska, J., Kotarska, M., Druzd‐Sitek, A., Konecki, R., and Mroz‐Zycinska, E.

Subjects
HODGKIN'S disease, RESEARCH teams, GEMCITABINE, LYMPHOMAS, DEXAMETHASONE
Abstract

Infections occurred in 18% ( I n i = 20) of pts during 2 BGD, 24% ( I n i = 27) if treatment was extended, majority of them were GRADE <3. B Introduction: b BURGUND is a phase II study evaluating the combination of bendamustine, gemcitabine and dexamethasone (BGD) as the first salvage therapy in patients with refractory or relapsed Hodgkin lymphoma (r/r HL). Pts received 1 ( I n i = 3), 2 ( I n i = 58), 3 ( I n i = 28), or 4 ( I n i = 23) cycles of BGD. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results